Evidence map›Paper›PMID 38608215›Full record

ArticleJCO clinical cancer informatics2024

Machine Learning-Based Survival Prediction Models for Progression-Free and Overall Survival in Advanced-Stage Hodgkin Lymphoma.

Rasmus Rask Kragh Jørgensen, Fanny Bergström, Sandra Eloranta, Marianne Tang Severinsen, Knut Bjøro Smeland, Alexander Fosså, Jacob Haaber Christensen, Martin Hutchings, Rasmus Bo Dahl-Sørensen, Peter Kamper and 8 more

Open access · hybridAbstract read
In one paragraph

Article in JCO clinical cancer informatics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
4.7field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Article
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 13 institutions in 11 countries.

Rasmus Rask Kragh JørgensenDepartment of Hematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.ORCID 0009-0000-7249-2196
Fanny BergströmClinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-0693-3851
Sandra ElorantaClinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-5806-0573
Marianne Tang SeverinsenDepartment of Hematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
Knut Bjøro SmelandDepartment of Oncology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-9832-4032
Alexander FossåDepartment of Oncology, Oslo University Hospital, Oslo, Norway.ORCID 0000-0002-4484-9319
Jacob Haaber ChristensenDepartment of Hematology, Odense University Hospital, Odense, Denmark.
Martin HutchingsDepartment of Hematology, Rigshospitalet, Copenhagen, Denmark.ORCID 0000-0003-3873-1741
Rasmus Bo Dahl-SørensenDepartment of Hematology, Zealand University Hospital, Roskilde, Denmark.
Peter KamperDepartment of Hematology, Aarhus University Hospital, Aarhus, Denmark.
Ingrid GlimeliusClinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-6158-3041
Karin E SmedbyClinical Epidemiology Division, Department of Medicine Solna, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-2104-3320
Susan K ParsonsDepartment of Medicine, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.ORCID 0000-0003-0282-6490
Angie Mae RoddayDepartment of Medicine, Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA.
Matthew J MaurerDepartment of Qualitative Health Sciences, Mayo Clinic, Rochester, MN.ORCID 0000-0002-1867-0526
Andrew M EvensDivision of Blood Disorders, Rutgers Cancer Institute New Jersey, New Brunswick, NJ.ORCID 0000-0002-6900-1824
Tarec C El-GalalyDepartment of Hematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
Lasse Hjort JakobsenDepartment of Hematology, Clinical Cancer Research Centre, Aalborg University Hospital, Aalborg, Denmark.
Novartis (Switzerland) · CHAalborg University Hospital · DKKarolinska Institutet · SEOslo University Hospital · NOAarhus University Hospital · DKKarolinska University Hospital · SEMayo Clinic · USOdense University Hospital · DKRutgers, The State University of New Jersey · USTufts Medical Center · USUniversity of Copenhagen · DKUppsala University · SEZealand University Hospital · DK

Funding

Modeling Multi-Source Data in Hodgkin LymphomaR01CA262265 · NCI · TUFTS MEDICAL CENTER · PI Andrew M Evens, Susan Kenyon Parsons · 2022 to 2026
$3.6M
NCI NIH HHS R01 CA262265
6 · The paper itself

Abstract

purposePatients diagnosed with advanced-stage Hodgkin lymphoma (aHL) have historically been risk-stratified using the International Prognostic Score (IPS). This study investigated if a machine learning (ML) approach could outperform existing models when it comes to predicting overall survival (OS) and progression-free survival (PFS). PATIENTS AND

methodsThis study used patient data from the Danish National Lymphoma Register for model development (development cohort). The ML model was developed using stacking, which combines several predictive survival models (Cox proportional hazard, flexible parametric model, IPS, principal component, penalized regression) into a single model, and was compared with two versions of IPS (IPS-3 and IPS-7) and the newly developed aHL international prognostic index (A-HIPI). Internal model validation was performed using nested cross-validation, and external validation was performed using patient data from the Swedish Lymphoma Register and Cancer Registry of Norway (validation cohort).

resultsIn total, 707 and 760 patients with aHL were included in the development and validation cohorts, respectively. Examining model performance for OS in the development cohort, the concordance index (C-index) for the ML model, IPS-7, IPS-3, and A-HIPI was found to be 0.789, 0.608, 0.650, and 0.768, respectively. The corresponding estimates in the validation cohort were 0.749, 0.700, 0.663, and 0.741. For PFS, the ML model achieved the highest C-index in both cohorts (0.665 in the development cohort and 0.691 in the validation cohort). The time-varying AUCs for both the ML model and the A-HIPI were consistently higher in both cohorts compared with the IPS models within the first 5 years after diagnosis.

conclusionThe new prognostic model for aHL on the basis of ML techniques demonstrated a substantial improvement compared with the IPS models, but yielded a limited improvement in predictive performance compared with the A-HIPI.

Indexed as

Hodgkin DiseaseArea Under CurveDisease-Free SurvivalHumansMachine LearningProgression-Free Survival

Identifiers

PMID38608215
PMCPMC11161240
OpenAlexW4394770131

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.